The main treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) is radical surgery, pulmonary thromboendarterectomy (PEA). However, about 40% of patients with CTEPH are inoperable due to distal pulmonary vascular lesions or the severity of hemodynamic disorders. Almost 30% of patients with CTEPH experience persistent or recurrent pulmonary hypertension after surgery, that requires a drug treatment with PAH-specific drugs. This review presents current data on the use of targeted therapy in patients with CTEPH. The review addresses the place, indications, and the evidence base for using the main groups of specific drugs, including stimulators of soluble guanylate cyclase, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, and prostacyclin analogues.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18087/cardio.2024.12.n2784 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Percutaneous closure of a traumatic ventricular septal defect: a case report and literature review.
Int J Emerg Med
January 2025
Departamento de Cardiología, Fundación Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia.
Background: Penetrating cardiac trauma is an entity with high pre and intrahospital mortality due to complications such as cardiac tamponade and massive hemothorax. A ventricular septal defect (VSD) occurs in 1-5% of cases and can present early or late. The management strategy for VSD resulting from penetrating cardiac trauma is uncertain.
View Article and Find Full Text PDFPulmonary artery denervation by noninvasive stereotactic radiotherapy: a pilot study in swine models of pulmonary hypertension.
Nat Commun
January 2025
Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Catheter-based pulmonary artery denervation (PADN) has achieved promising outcomes to treat pulmonary hypertension (PH). We herein present stereotactic body radiotherapy (SBRT) as a novel noninvasive approach for PADN. A single fraction of 15 Gy, 20 Gy or 25 Gy was delivered for PADN in a thromboxane A2 (TxA2) - induced acute PH swine model.
View Article and Find Full Text PDFValidation of a non-invasive filling pressure (NIFP) device for measuring cardiac pressure and assessing congestion levels in patients with heart failure.
Int J Cardiol
January 2025
State Key Laboratory for Innovation and Transformation of Luobing Theory, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Electronic address:
Background: Heart failure (HF) is a high-burden clinical syndrome characterized by intravascular and extravascular congestion, impacting patients' outcomes. Current diagnostic methods for assessing intravascular congestion, including right heart catheterization (RHC), have some limitations. There is a need for accurate, stable, and widely applicable non-invasive measurement methods to improve HF diagnosis and treatment.
View Article and Find Full Text PDFSustained release of Ambrisentan Solid Lipid Nanoparticles for the treatment of Hypertension: Melt Emulsification Method.
Ann Pharm Fr
January 2025
SVKM's NMIMS School of Pharmacy and Technology Management Shirpur, Dhule, India-425405, India; SVKM Institute of Pharmacy, Dhule, Maharashtra-424001, India. Electronic address:
Objective: The beneficial usefulness is limited because of its deprived solubility and bioavailability. The recent work deals with the advancement of solid lipid nanoparticles of Ambrisentan for the effective therapy of pulmonary hypertension intended for oral delivery.
Material And Methods: The solid lipid nanoparticles of Ambrisentan were developed using the melt-emulsification method.
Concomitant Pulmonary Vein Isolation for induced Atrial fibrillation to reduce future risk of atrial fibrillation following Ablation for Isolated Atrial Flutter.
Heart Rhythm
January 2025
Department of Cardiology, The affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Background: A significant proportion of patients with isolated atrial flutter (AFL) will develop atrial fibrillation (AF) following cavotricuspid isthmus (CTI) ablation.
Objective: To determine whether concomitant pulmonary vein isolation (PVI) could reduce the incidence of new-onset atrial fibrillation (NOAF) in the setting of inducible AF following CTI ablation.
Methods: A total of 275 consecutive patients with isolated AFL who successfully underwent CTI ablation were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!